Scientific evidence

Integrating skin cancer–related technologies into clinical practice

Oct 2017

11-member Melanoma Evolving Diagnostic Technologies Integration Group (MEDTIG) derived an algorithmic approach to systematically facilitate incorporating these technologies into the evaluation and management of suspicious PSLs.

Author: Winkelmann R, et al.

Publication: Dermatologic Clinics

Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

Aug 2017

Prospective evaluation of the GEP performance in patients enrolled in two clinical registries for three primary endpoints recurrence-free (RFS), distant metastasis-free (DMFS), and overall survival (OS).

Author: Hsueh E, et al.

Publication: Journal of Hematology and Oncology

Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma

Aug 2017

Detection of the field effect in the clinical setting with validated, cost-effective diagnostic assays may increase the detection of HGD and EAC.

Author: DeWard AD, et al.

Publication: Translational Cancer Research

Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics

Aug 2017

A 15-gene expression profile test has been clinically validated and is widely utilized in newly diagnosed uveal melanoma (UM) patients to assess metastatic potentila of the tumor. As most patients are treated with eye-sparing rediotherapy, there is limited tumor tissue available for testing, and technical reliability and success of prognostic testing are critical. This study assessed the analytical performance of the 15-gene expression test for UM and the correlation of molecular class with pathologic characteristics.

Author: Plasseraud K, et al.

Publication: Diagnostic Pathology

Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes

Jul 2017

Large outcomes-proven validation cohort establishes high levels of sensitivity and specificity in melanomas with proven distant metastasis and nevi with 6+ years of event free follow-up.

Author: Ko J, et al.

Publication: Cancer Epidemiology, Biomarkers, and Prevention

Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists clinical management decisions

May 2017

Risk appropriate management recommendations for implementing SLNB and imaging were more likely to be made following incorporation of DecisionDx-Melanoma test results.

Author: Farberg A, et al.

Publication: Journal of Drugs and Dermatology

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer individualized melanoma patient outcome prediction tool with a 31-gene expression profile–based classification

May 2017

Comparison and accuracy of the GEP in combination with risk determined using the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.

Author: Ferris L, et al.

Publication: Journal of the American Academy of Dermatology

Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol

Mar 2017

Pharmacogenetics guidance resulted in frequent modifications of the analgesic program, resulting in excellent analgesia with a 50% reduction in narcotic consumption, and a reduced incidence of analgesic related side effects compared to our standard ERP.

Author: Senagore A, et al.

Publication: The American Journal of Surgery

A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus

Feb 2017

A tissue systems pathology test may provide an objective method to facilitate earlier therapeutic intervention of Barrett's esophagus patients.

Author: Critchley-Thorne RJ, et al.

Publication: Cancer Epidemiology, Biomarkers & Prevention

The influence of a gene expression signature on the treatment of diagnostically challenging melanocytic lesions

Jan 2017

MyPath Melanoma guides dermatologists in treatment decisions leading to a 72% reduction in re-excisions when the GEP result is benign.

Author: Cockerell C, et al.

Publication: Personalized Medicine

Contribution of pharmacogenetic testing to modeled medication change recommendations in a long-term care population with polypharmacy

Dec 2016

Among long-term care facility residents, polypharmacy is common, and often appropriate, given the need to treat multiple, complex, chronic conditions. Polypharmacy has, however, been associated with increased healthcare costs, adverse drug events, and drug interactions. The current study evaluates the potential medication cost savings of adding personalized pharmacogenetic information to traditional medication management strategies.

Author: Sugarman E, et al.

Publication: Drugs Aging

An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi

Oct 2016

Establishes the performance of the gene expression signature in prospectively submitted cases with triple concordant diagnosis.

Author: Clarke L, et al.

Publication: Cancer